Exagen

Exagen XGN Stock

$3.61   -5.000001%
Add to favorites
Market Cap
$92.10M
LOW - HIGH [24H]
$3.48 - $3.90
VOLUME [24H]
$508.83K
P/E Ratio
0
Earnings per share
-$0.76
ISIN
US30068X1037
Price   Prediction

Exagen Price Chart

Sorry, that's all we've gotfor now...

Exagen (XGN) stock price today is 3.61 USD on Tech Market Middle (-5% on the day). Updated .

Exagen XGN Financial and Trading Overview

Exagen stock price 3.61 USD
Previous Close 3.8 USD
Open 3.77 USD
Bid 5.1 USD x 200
Ask 8.21 USD x 200
Day's Range 3.48 - 3.9 USD
52 Week Range 2.59 - 9.22 USD
Volume 508.83K USD
Avg. Volume 466.41K USD
Market Cap 92.1M USD
Beta (5Y Monthly) 2.241
PE Ratio (TTM) N/A
EPS (TTM) -0.76 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 9.43 USD

XGN Valuation Measures

Enterprise Value 92.77M USD
Trailing P/E N/A
Forward P/E -7.22
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 1.2739985
Price/Book (mrq) 6.6605163
Enterprise Value/Revenue 1.283
Enterprise Value/EBITDA -8.099

Trading Information

Exagen Stock Price History

Beta (5Y Monthly) 2.241
52-Week Change -50.065%
S&P500 52-Week Change 8.67%
52 Week High 9.22 USD
52 Week Low 2.59 USD
50-Day Moving Average 7.43 USD
200-Day Moving Average 5.13 USD

XGN Share Statistics

Avg. Volume (3 month) 466.41K USD
Avg. Daily Volume (10-Days) 1.36M USD
Shares Outstanding 25.51M
Float 17.86M
Short Ratio 1.99
% Held by Insiders 22.66%
% Held by Institutions 51.88%
Shares Short 727.46K
Short % of Float 3.14%
Short % of Shares Outstanding 2.85%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin -25.13%
Operating Margin (ttm) -19.27%
Gross Margin 58.73%
EBITDA Margin -15.84%

Management Effectiveness

Return on Assets (ttm) -14.73%
Return on Equity (ttm) -113.88%

Income Statement

Revenue (ttm) 72.3M USD
Revenue Per Share (ttm) 3 USD
Quarterly Revenue Growth (yoy) 6.80%
Gross Profit (ttm) 42.46M USD
EBITDA -11455000 USD
Net Income Avi to Common (ttm) -18172000 USD
Diluted EPS (ttm) -0.72
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 28.09M USD
Total Cash Per Share (mrq) 1.1 USD
Total Debt (mrq) 28.76M USD
Total Debt/Equity (mrq) 208.79 USD
Current Ratio (mrq) 3.46
Book Value Per Share (mrq) 0.542

Cash Flow Statement

Operating Cash Flow (ttm) -12017000 USD
Levered Free Cash Flow (ttm) -5707875 USD

Profile of Exagen

Country United States
State CA
City Vista
Address 1261 Liberty Way
ZIP 92081
Phone 760 560 1501
Website https://www.exagen.com
Industry Diagnostics & Research
Sector(s) Healthcare
Full Time Employees 216

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Q&A For Exagen Stock

What is a current XGN stock price?

Exagen XGN stock price today per share is 3.61 USD.

How to purchase Exagen stock?

You can buy XGN shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Exagen?

The stock symbol or ticker of Exagen is XGN.

Which industry does the Exagen company belong to?

The Exagen industry is Diagnostics & Research.

How many shares does Exagen have in circulation?

The max supply of Exagen shares is 25.51M.

What is Exagen Price to Earnings Ratio (PE Ratio)?

Exagen PE Ratio is now.

What was Exagen earnings per share over the trailing 12 months (TTM)?

Exagen EPS is -0.76 USD over the trailing 12 months.

Which sector does the Exagen company belong to?

The Exagen sector is Healthcare.

Exagen XGN included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 22617.73 USD —
-5.28
10.6B USD — 22513.01 USD — 23837.76 USD — — 10.6B USD —
us US Tech Global Market Composite NQGM US 1743.91 USD —
-3.66
— — 1738.23 USD — 1808.43 USD — — — —
us US Tech Health Care IXHC US 1282.67 USD —
-1.79
— — 1279.99 USD — 1317.94 USD — — — —
$2.08T
Total marketcap
$112.06B
Total volume
BTC 57.94%   •   ETH 9.83%
Dominance
Select currency